Psyence Biomedical Ltd. (PBM)
| Market Cap | 5.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.16M |
| Shares Out | 3.03M |
| EPS (ttm) | -588.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73,486 |
| Open | 1.750 |
| Previous Close | 1.770 |
| Day's Range | 1.700 - 1.850 |
| 52-Week Range | 1.510 - 593.250 |
| Beta | -0.44 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 2, 2025 |
About PBM
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in t... [Read more]
Financial Performance
Financial StatementsNews
Psyence Biomed Announces Closing of $2.0 Million Private Placement
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for ...
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), h...
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin Extract Vancouver, British Columbia--(Newsfile Corp. ...
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
Psyence Biomed obtains exclusive worldwide supply rights to Optimi's GMP-certified, nature-derived psilocybin for its drug development and commercialization initiatives in Palliative Care Psyence Biom...
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-e...
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened ...
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation...
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Compan...
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen...
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen...
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder, as previously announced PsyLabs to exclusive...
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap A...
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its pre...
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural ...
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and ...
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorde...
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determi...
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
Patient screening to be initiated imminently; first subject expected to be randomized into the study in October Patient screening to be initiated imminently; first subject expected to be randomized in...
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD)
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously annou...
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived psilocybin-based therapeutics, today announced that...